Corneal neovascularization can reduce visual acuity. GAbinding protein (GABP) is a transcription factor that regulates the expression of target genes including vascular endothelial growth factor (VEGF) and roundabout4 (Robo4), which participate in pathologic angiogenesis. We assessed whether intraocular injection of the GABP gene affects the growth of new corneal blood vessels in a mouse ocular neovascularization model. Transfection of human GABPa and GABPb gene (GABPa/b) into human conjunctival epithelial cells resulted in decreased VEGF and Robo4 expression. Three groups of mice underwent chemical and mechanical denudation of the corneal epithelium. Subsequently, two groups were administered subconjunctival injection of lipoplexes carrying plasmid DNA encoding for human GABPa/b or an empty plasmid DNA at 1-week intervals. The third group served as an experimental control. In vivo delivery of human GABPa/b into mouse neovascularized cornea reduced VEGF and Robo4 gene expression. Biomicroscopic examination showed that, at 1 week after one or two injections, GABPa/b-treated eyes had significantly less neovascularized corneal area than did eyes treated with the empty vector. Histologic examination showed significantly less vascularized area and fewer blood vessels in the GABP-treated group at 1 week after injections. However, these angiosuppressive effects were weakened at 2 weeks after injections. Our results indicate that subconjunctival GABP gene delivery delays corneal neovascularization for up to 2 weeks in a mouse model of deliberate corneal injury.
Introduction
Corneal neovascularization is characterized by the ingrowth of new vessels from the limbus caused by the loss of the limbal stem cell barrier and frequently results in vision impairment or blindness. Corneal neovascularization is usually associated with inflammatory or infectious disorders of the ocular surface and is often accompanied by stromal edema, scarring, lipid deposits and keratitis; corneal neovascularization can also occur following keratoplasty. 1 Angiogenesis is initiated when the balance between angiogenic and antiangiogenic factors is shifted toward the angiogenic factors. [2] [3] [4] Various angiogenic factors mediate corneal neovascularization: vascular endothelial growth factor (VEGF), basic fibroblast growth factor, matrix metalloproteinase and insulin-like growth factor-1. Among these, VEGF is reported to be the primary mediator of neovascularization in the eye 5 and is elevated in inflamed and vascularized corneas of rats and humans. 6 Thus, reducing VEGF levels is the most common approach for inhibiting corneal neovascularization in corneal gene therapy studies. 7, 8 The imbalance between angiogenic and antiangiogenic factors responsible for pathologic angiogenesis may also result from downregulation of inhibitors of blood vessel growth. Recognition of the potential benefits of controlling angiogenesis has led to a search for inhibitors of angiogenesis, and there has been considerable recent progress in identifying molecular signals that participate in ocular neovascularization. Reestablishing the balance between angiogenic and antiangiogenic factors by ocular gene transfer to block stimulators or increase the expression of endogenous inhibitors is a promising therapeutic approach. 7 Recent studies have shown that angiogenesis inhibitors, such as endostatin, angiostatin, somatostatin, tissue inhibitor of metalloproteinase-3, peptide derived from thrombospondin-1, prolactin and brain-specific angiogenesis inhibitor 1 (BAI1), can inhibit corneal neovascularization and maintain corneal avascularity. [9] [10] [11] [12] [13] [14] [15] [16] GA-binding protein (GABP) is a ubiquitously expressed nuclear transcription factor that is involved in a broad range of cellular processes and that regulates target gene expression in the cell cycle and cellular metabolism. 17 GABP is composed of two subunits: GABPa contains the erythroblast transformation-specific DNA-binding domain, whereas the substitutable subunit, GABPb or GABPg, contains ankyrin repeats and the transcriptional activation domain. Both GABPb and GABPg contain a nuclear localization signal; however, GABPa does not, and its entry into the nucleus absolutely requires the concomitant expression of either GABPb or GABPg. Therefore, GABPb or GABPg should bind GABPa in the cytoplasm to assist GABPa transport into the nucleus. [18] [19] [20] GABP is now also recognized as a key transcriptional regulator of dynamically regulated, lineage-restricted genes, especially in myeloid cells and at the neuromuscular junction, and acts as an integrator of the cellular signaling pathway by regulating key hormones and transmembrane receptors. 17 Recently, we found that the heteromeric complex of GABP (GABPa/b) acts as a transcriptional repressor and thereby inhibits VEGF expression in SH-SY5Y neuroblastoma and green monkey kidney epithelial (CV-1) cells. 21 This suggested testing the possibility of using GABP to control neovascularization of the ocular surface. Ectopic expression of GABP has been reported to induce quiescent cells to reenter the cell cycle, which suggests that GABP is necessary and sufficient for reentry into the cell cycle. 22 Moreover, SP1 transcription factor and GABP bind to the human roundabout4 (Robo4) promoter in primary endothelial cells from human coronary artery and induce promoter activation. 23 Robo4 is expressed exclusively in endothelial cells and has been implicated in endothelial cell migration and angiogenesis, 24, 25 and also in stabilizing the vasculature. 26 Therefore, in the present study, we investigated whether in vivo subconjunctival gene delivery of GABP transcription factor affects gene expression pattern of Robo4 and VEGF in the corneal neovascularization induced by chemical and mechanical injuries. Both genes are important in pathologic angiogenesis and modulate experimental corneal neovascularization process in a mouse model.
Results
Decreased VEGF and Robo4 expression after GABPa/ b gene transfer in conjunctival epithelial cells GABPa/b was reported to act both as a transcriptional repressor of VEGF expression in SH-SY5Y and CV-1 cells 21 and as an activator with SP1 of the human Robo4 promoter in primary endothelial cells. 23 We chose human Chang conjunctival epithelial cells to test the expression of the GABPa/b gene in the conjunctiva and cornea by transiently transfecting these cells with increasing doses of lipoplexes carrying a plasmid encoding for the human GABPa and GABPb (GABPa/b) genes.
Expression of VEGF mRNA or protein in conjunctival epithelial cells was decreased after transfection with GABPa/b gene (Figure 1a ), indicating that GABPa/b also acts as a transcriptional repressor of VEGF in conjunctival epithelial cells. Unexpectedly, Robo4 mRNA, an endothelial-specific gene, was expressed in conjunctival epithelial cells and was markedly decreased after GABPa/b transfection ( Figure 1a ). This suggests that GABP can act as a transcriptional repressor, rather than as an activator, of Robo4 expression in conjunctival epithelial cells.
Exogenous GABPa expression in mouse cornea after subconjunctival GABPa/b gene injection To determine whether exogenous human GABP would be expressed in the mouse cornea after local gene transfer in the corneal angiogenesis model, we used lipoplexes that carry a plasmid DNA encoding for the human GABPa/b gene. At 3 and 5 days after subconjunctival injection of the human GABPa/b plasmid, human GABPa mRNA expression was observed in the mouse cornea (Figure 1b) , thus indicating that the exogenous human gene was expressed. Expression was observed until 7 days after subconjunctival gene injection (data not shown). VEGF and Robo4 mRNA, which are expressed primarily in the endothelium, 26 were ex- There was no expression of hGABPa after injection of lipoplexes carrying empty plasmid DNA (V3, V5). Also, expression of exogenous human GABPa/b in mouse cornea markedly decreased mouse VEGF (mVEGF) and mouse Robo4 mRNA (mRobo4) expression at 3 days (G3) after injection. Excised corneas from five mice per group were pooled for RNA extraction. C3, cornea harvested 3 days after corneal denudation without gene injection.
GABP gene delivery delays corneal neovascularization KC Yoon et al pressed in the cornea that was denudated but not treated ( Figure 1b ). This suggests that corneal neovascularization may occur after corneal injury. Also, as in the conjunctival epithelial cells, the expression of VEGF and Robo4 mRNA was markedly decreased in the mouse cornea at 3 days after the subconjunctival injection of the human GABPa/b plasmid, but gradually recovered by 5 days after injection. Thus, the lipoplexes carrying the GABPa/ b plasmid DNA or empty plasmid DNA were injected at 1-week intervals to maintain transgene expression, just as in our previous study. 16 Decreased in vivo VEGF and Robo4 expression in the cornea after GABPa/b gene injection 
Quantitative biomicroscopic analysis shows less neovascularized corneal area after GABP gene delivery
We tested whether the injected GABPa/b gene could inhibit corneal neovascularization in a mouse model by biomicroscopic examination. The lipoplexes carrying the GABPa/b plasmid DNA or the empty plasmid DNA were applied subconjunctivally to each eye at 1 week after debridement. Mean values of neovascularized corneal area in GABPa/b-or empty-vector-treated eyes were measured at 3, 7 and 14 days after one or two injections and were compared with experimental control eyes at corresponding periods after corneal denudation. Three days after the one-injection treatment of GABPa/b or empty plasmid DNA, the GABPa/b-treated group showed less neovascular growth (Figure 3c ) than did the empty-vector-treated group (Figure 3d ) or the experimental control group (data not shown). The mean percentages of neovascularized corneal area to the total corneal area as calculated by morphometric analyses of the biomicroscopic images in GABPa/b-treated, emptyvector-treated and experimental control eyes are depicted in Figure 4 . Three days after one-injection treatment, GABPa/b-treated eyes had significantly less neovascular corneal area than did empty-vector-treated (25.4%, Po0.05) or experimental control eyes (26.7%, Po0.05) (Figure 4a ).
Seven days after one-injection treatment, the GABPa/ b-treated group showed less neovascular growth ( Figure  3e ) than did the empty-vector-treated group (Figure 3f ) or the experimental control group (Figure 3a) . Thus, 7 days after one-injection treatment, GABPa/b-treated eyes had significantly less neovascular corneal area than GABP gene delivery delays corneal neovascularization KC Yoon et al did empty-vector-treated (34.6%, Po0.01) or experimental control eyes (33.5%, Po0.01). Fourteen days after oneinjection treatment, GABPa/b-treated eyes had less neovascular corneal area but the difference was not significant compared with empty-vector-treated or experimental control eyes (Figure 4a ).
To evaluate whether the frequency of gene delivery affected the antiangiogenic results of GABPa/b on neovascularized cornea, we gave two injections, 1 week apart, of lipoplexes that carry the GABPa/b plasmid or empty plasmid DNA. Three days after this two-injection treatment, GABPa/b-treated eyes had significantly less neovascular corneal area than did empty-vector-treated (25.5%, Po0.01) or experimental control eyes (24.4%, Po0.01) (Figure 4b ). Seven days after the second gene injection, the GABPa/b-treated group showed less neovascular growth (Figure 3g ) than did the emptyvector-treated group (Figure 3h ) or experimental control group (Figure 3b) , and GABPa/b-treated eyes had significantly less neovascular corneal area than did empty-vector-treated (20.3%, Po0.01) or experimental control eyes (20.3%, Po0.01) (Figure 4b ). Fourteen days after two-injection treatment, however, the GABPa/btreated eyes had less neovascular corneal area, but the difference was not significant compared with empty-vector-treated or experimental control eyes (Figure 4b) .
Overall, there were no practical or significant differences in the magnitude of the antiangiogenic effect of GABPa/b on the neovascularized cornea between mice treated with one injection compared to two injections.
Histologic analysis shows less vascularized area and fewer vessels in mouse cornea treated by subconjunctival GABP gene delivery Suppression of experimental corneal angiogenesis by GABPa/b gene delivery was also studied by histologic examination of corneas excised from empty-vector-and GABPa/b-injected mice. We used toluidine blue staining as a molecular method to detect neovascularization. 27, 28 After injury, the experimental control group showed more neovascular growth (Figures 5b and d) Table 1 . Seven days after one-injection treatment of GABPa/b or empty plasmid DNA, the mean neovascular area and the mean number of vessels in three corneal sections of each mouse in GABP-treated eyes were significantly less than those in empty-vector-treated eyes (Po0.01 and o0.05, respectively) and experimental control eyes (Po0.01 and o0.05, respectively). Also, 1 week after two-injection treatment of GABPa/b or empty plasmid DNA, the mean neovascular area and the mean number of vessels in three corneal sections of each mouse were significantly less than those in empty-vector-treated eyes (Po0.05 and o0.05, respectively) (see Table 1 ).
However, 2 weeks after one-or two-injection treatment, the mean neovascular area and number of vessels in GABP-treated eyes were not significantly different than in empty-vector-treated eyes (Table 1) . Thus, subconjunctival GABPa/b gene delivery significantly reduced the neovascular area and the number of vessels at 1 week, but not 2 weeks, after treatments with either one or two injections.
Discussion
The specialized anatomy of the eye is such that highly vascularized and avascular tissues exist side by side. 29 This requires tight regulation of the vascular growth process in avascular corneal tissue, which is maintained by the expression of soluble VEGF receptor-1 (sFlt-1). 30 Under certain inflammatory conditions, however, avascular cornea may be subject to unwanted new blood vessel growth from the limbus caused by the loss of the limbal stem cell barrier.
Corneal neovascularization is a serious vision-threatening complication associated with corneal infection, chemical injury or corneal trauma. 2, 7, 8 Angiogenesis is initiated when the balance between angiogenic and antiangiogenic factors is shifted toward the angiogenic factors. Accordingly, neovascularization requires not only the upregulation of angiogenic factors, but also the downregulation of antiangiogenic factors. 2, 4 Moreover, the imbalance accountable for pathologic angiogenesis may also be caused by downregulation of inhibitors of angiogenesis, and we recently reported that the BAI1 gene reduces corneal neovascularization in a rabbit model. 16 In the present study, we examined the possibility that subconjunctival delivery of the GABP transcription factor to neovascularized cornea could affect the expression patterns of VEGF and Robo4, which were reported to be transcriptionally regulated by GABP and to be critical regulatory proteins in pathologic angiogenesis. 21, 23, 25, 26 Using this approach, we observed for the first time that GABP could delay new vessel formation in a mouse neovascularized cornea for up to 2 weeks after subconjunctival injection of lipoplexes carrying the GABPa/b plasmid DNA adjacent to the corneal neovascular area. We found that gene delivery of the GABPa/b plasmid DNA reduced VEGF and Robo4 expression in conjunctival epithelial cells and in mouse neovascularized cornea, and that GABPa/b-injected cornea had significantly less neovascular area and fewer vessels than did the emptyvector-treated or experimental control groups. Thus, we confirmed that the transcriptionally active GABPa/b heteromeric complex acts as a repressor of in vivo VEGF and Robo4 expression, and thereby leads to a reduction of corneal neovascularization in a mouse model.
Although neovascularization was significantly suppressed at 7 days after treatment, the suppressive effect decreased at 2 weeks after gene injection. This finding indicates that the duration of repressed neovascularization by GABP delivery is somewhat short compared with that of direct VEGF suppression in rat cornea by adenoviral antisense RNA delivery, in which reduced neovascularization is seen 14 days after injury, 6 but equivalent to that of direct VEGF knockdown in mouse cornea by siRNA delivery, in which reduced neovascularization is seen 7 days after implantation of CpGcontaining oligonucleotides. 31 In addition, subconjunctival injection of bevacizumab, an anti-VEGF antibody, was reported to induce regression of experimental corneal neovascularization up to 2 weeks in animal models, 32, 33 and partial regression of corneal neovascularization was reported in short-term studies in humans. 34 These reports suggest that the vascular regression induced in the cornea by blocking VEGF action alone is partial and transient. 
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GABP was reported to act as a transcriptional activator with SP1 of human Robo4, 23 which has been implicated in endothelial cell migration, angiogenesis and vascular development in vertebrates. 24, 25 Also, a GABP-binding motif is necessary for mediating Robo4 expression in the intact endothelium. 35 By contrast, the Robo4 receptor is essential for Slit2-dependent inhibition of VEGF-165-induced pulmonary endothelial cell migration, tube formation, and permeability in vitro and for inhibiting VEGF-165-driven vascular leaking in vivo by blocking Src family kinase activation. Moreover, in mouse models of oxygen-induced retinal and laser-induced choroidal vascular disease, Slit2 inhibited angiogenesis and vascular leaking, whereas deletion of the Robo4 gene enhanced these pathologic processes. 26 Those findings suggest that Robo4 is involved in stabilizing the vasculature and that activating the Robo4 receptor may have therapeutic application in diseases characterized by excessive pathologic angiogenesis and vascular leaking. 26 In this study, however, we observed that forced expression of GABPa/b in the mouse cornea and in cultured human conjunctival epithelial cells suppressed Robo4 mRNA expression, thus suggesting the presence Figure 5 Light micrographs of corneas in an experimental control eye after corneal denudation and the effects of GABPa/b gene delivery on corneal angiogenesis. Representative micrographs of toluidine blue-stained corneas, given lipoplexes carrying the empty plasmid DNA or the GABPa/b gene are shown. The untreated absolute control group at 2 (a) and 3 (c) weeks showed no neovascularization, whereas the experimental control group at 2 (b) and 3 (d) weeks showed neovascular formation. Vascularity was examined 1 week after 1 injection of GABPa/b (e) or empty vector (f), at 2 weeks after one injection of GABPa/b (g) or vector (h), at 1 week after two injections of GABPa/b (i) or vector (j), and at 2 weeks after two injections of GABPa/b (k) or vector (l). GABPa/b-treated corneas showed significantly fewer vessels and smaller areas of neovascularization than did empty vector-treated corneas. Scale bar ¼ 20 mm.
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KC Yoon et al of regional variation in the effect of GABP on Robo4 expression in the eye, especially in the avascular cornea. The molecular mechanisms of Robo4 expression in neovascularized cornea are not entirely elucidated at present. However, because VEGF and Robo4 are not expressed in normal avascular cornea but are expressed primarily in neovascularized corneal endothelium in the mouse corneal injury model used in this study (Figure 2 ), we hypothesize that suppression of Robo4 and VEGF by GABP gene delivery could be beneficial for reducing corneal neovascularization. In addition, we cannot rule out the possibility that the GABP expression driven by the injected lipoplexes was simply not maintained at a sufficient level to reduce the angiogenic stimulus. Considering all our results together, we hypothesize that after subconjunctival GABPa/b injection, overexpressed GABPa/b in the injected area may induce conjunctival vascular endothelial cells to reenter the cell cycle, 22 while at the same time suppress or delay corneal angiogenesis by transcriptional repression of VEGF and Robo4 in the neovascularized cornea. Thus, in concert with these potential underlying mechanisms of GABP, we observed partial recovery of angiogenesis 2 weeks after GABP injection (Table 1) . Therefore, it seems that GABP gene delivery into the neovascularized cornea may result in a relatively shortterm suppression of angiogenesis, in which the balance between angiogenic and antiangiogenic processes is reestablished around 2 weeks after gene injection. This suggests that the application of GABP gene therapy in treating corneal neovascularization may require further experimental and preclinical studies.
Materials and methods

Animals
The study was performed with C57BL/6 mice weighing between 20 and 25 g. Prior approval of the experimental protocol was obtained from the Chonnam National University Medical School Research Institutional Animal Care and Use Committee. Animal maintenance and all in vivo experiments were performed in accordance with institutional guidelines and the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research.
Plasmids, cell culture and RT-PCR
The pFLAG mammalian expression vector (Eastman Kodak, Rochester, NY, USA), which has a cytomegalovirus promoter, was used for GABPa and GABPb expression. Two microliters of empty pFLAG vector (2 mg) or pFLAG-GABP plasmid (2 mg; 1 mg GABPa and 1 mg of GABPb plasmid DNA) was mixed with 1 ml of FuGENE 6 (Roche, Indianapolis, IN, USA), to which 17 ml of serum-free medium was added to make a total volume of 20 ml.
Human Chang conjunctival epithelial cells (clone 1-5c-4) were obtained from the Korean Cell Line Bank and were cultured in six-well plates with RPMI 1640 containing 10% fetal bovine serum and antibiotic/antimycotic solution. Cells were then transfected with pFLAG-tagged GABPa and GABPb or empty pFLAG vector using FuGENE 6 according to the manufacturer's protocol. Cell lysates were prepared, resolved by SDS-polyacrylamide gel electrophoresis, transferred and blotted with anti-VEGF (NeoMarkers, Fremont, CA, USA) as described. 21 Total RNAs were prepared from cultured cells or excised pooled corneas. Total RNA (400 ng) was reversetranscribed, as described elsewhere, 16 with random primers and MMLV by the use of RT-PCR kit (Invitrogen, Carlsbad, CA, USA). PCR consisted of 30-35 cycles of the following conditions: denaturing for 50 s at 94 1C, annealing for 50 s and extension for 1 min at 72 1C. The amplification products were analyzed on agarose gels and visualized. The annealing temperature was 60 1C for hVEGF, b-actin, and GAPDH and 58 1C for hRobo4. PCR primers for hVEGF: S1, 5 0 -GCAGACCAAAG-AAAGAT AGAGCAAG-3 0 , and AS1, 5 0 -CGCCTCGGCTTGTCACAT-3 0 ; hRobo4: S1, 5 0 -CCAGTAGACCTG-TCTGCCTCCTTT-3 0 , and AS1, 5 0 -GGAGCCATAAAAAGTGCTGGTGTC-3 0 .
Mouse model of corneal neovascularization
General anesthesia was induced with an intramuscular injection of 50 mg kg À1 ketamine hydrochloride and 10 mg kg À1 xylazine. After instillation of topical proparacaine, the entire corneal surface was contacted with 2 ml of 0.15 mM NaOH for 5 s. The corneal surface was then rinsed with sterile saline, and the corneal and limbal epithelia were removed with a corneal knife in a rotary motion parallel to the limbus. Levofloxacin eyedrops (Cravit, Santen, Osaka, Japan) were instilled immediately after epithelial debridement.
Experimental design
One week after epithelial debridement, lipoplexes carrying the GABPa/b plasmid DNA or empty plasmid DNA were injected into the bulbar conjunctiva. For identifica- GABP gene delivery delays corneal neovascularization KC Yoon et al tion of gene expression, mice were treated by subconjunctival injection (20 ml) of lipoplexes prepared as described above into the right eye. In one group (n ¼ 15), the lipoplexes carried 1 mg of GABPa and 1 mg of GABPb, whereas in the other group (n ¼ 15), the lipoplexes carried 2 mg of an empty plasmid DNA. For each group, five eyes were used for corneal RNA preparation after 3 days, five eyes were used for immunohistochemistry after 3 days and five eyes were used for corneal RNA extraction after 5 days. For RNA preparation, excised corneas were pooled per each time point. For biomicroscopic and histologic examinations, mice were treated by subconjunctival injection (20 ml) of lipoplexes. In one group (n ¼ 12), the lipoplexes carried 1 mg of GABPa and 1 mg of GABPb, whereas in the other group (n ¼ 12), the lipoplexes carried 2 mg of an empty plasmid DNA. For each group, six mice were examined 1 week after injection, and the remaining six mice were evaluated after 2 weeks. The right eyes of 12 mice were not injected after epithelial debridement and served as experimental controls. Four eyes that received neither treatment nor epithelial debridement served as untreated absolute controls.
In a separate examination, 1 week after debridement, subconjunctival injections of lipoplexes carrying the GABPa/b plasmid DNA (n ¼ 12) or empty vector (n ¼ 12) were performed twice at 1-week intervals into the right eye, as described above. Also, experimental controls (n ¼ 12) and untreated absolute controls (n ¼ 4) were used.
Examination of GABP, VEGF and Robo4 expression in gene-injected cornea
The expression of exogenous human GABPa/b, mouse VEGF and mouse Robo4 in the mouse cornea was confirmed via reverse transcription (RT)-PCR and immunohistochemical analyses. Primer sets were designed to recognize the FLAG-specific portions of the pFLAG-GABP gene (FLAG sense, 5 0 -GACTACAAAGAC GATGACGAC-3 0 , and GABPa antisense, 5 0 -ATATCTTG CAGACAAATTT-3 0 ). Specific PCR primers for mouse VEGF and Robo4 were designed (mVEGF: sense, 5 0 -CCGAGAAGAGAGGGGAGGAA-3 0 , and antisense, 5 0 -GTTCATGGTTTCGGAGGCCC-3 0 ; mRobo4: sense, 5 0 -TCCAGGGACGGCCACAAGAT-3 0 , and antisense, 5 0 -GACCAGGGGTTTCCCGTCTT-3 0 ).
Analysis of corneal neovascularization by biomicroscopic examination
All mice were photographed at a standard magnification 1 day before injection and on days 3, 7 and 14 after injection. After anesthesia with 50 mg kg À1 of ketamine hydrochloride and 10 mg kg À1 of xylazine, images of corneal neovascularization were captured with a camera (F-801s; Nikon, Miyagi, Japan) attached to a slit-lamp biomicroscope (FS-3; Nikon, Kanagawa, Japan). The images were analyzed by using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD, USA) as described. 16 The images were resolved at 624 Â 480 pixels and converted to a tagged information file format. Neovascularization in the entire cornea was quantitated in a blinded manner to minimize sampling bias. The total surface area of the cornea was outlined, using the innermost vessel of the limbal arcade as the border. The area of corneal vasculature was outlined with the computer mouse, the total neovascularization area was then normalized to the total corneal area, and the percentage of the cornea covered by vessels was calculated by morphometric analysis.
Analysis of corneal neovascularization by histologic examination
Mice (n ¼ 6) were anesthetized with 50 mg kg À1 of ketamine hydrochloride and 10 mg kg À1 of xylazine on day 7, and the common carotid artery was exposed. This artery was then flushed through a catheter with phosphate-buffered saline, followed by 4% paraformaldehyde. The eyes were enucleated and immediately placed into the same fixative. After fixation, the corneas were excised and immersed in 4% paraformaldehyde fixative at 4 1C overnight. The tissue blocks were washed, dehydrated, embedded in paraffin, cut in 6-mm sections and mounted. The tissue sections were deparaffinized, rehydrated, rinsed, and stained with eNOS and VEGF (Santa Cruz Biotech, Santa Cruz, CA, USA) or Robo4 antibody (Abcam, Cambridge, UK) and examined as described. 16 To determine the degree of induced angiogenesis, we stained sections with toluidine blue. 27, 28 Three representative sections obtained from each cornea of experimental control, empty-vector-treated or GABPa/b-treated groups were analyzed with a microscope (Olympus, Tokyo, Japan) as described. 16 The images were captured with a Spot digital camera (Media Cybernetics) and morphometric analyses were performed using ImagePro Plus software. The whole field at a magnification of Â 400 was examined for each cross section. The sum and mean of the vascularized area of each vessel and the number of vessels per section were determined.
Statistical analysis
Results are expressed as mean±s.e.m. The statistical significance of differences among the experimental control and empty-vector-and GABPa/b-treated groups was determined by the Kruskal-Wallis test with SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). The statistical significance of differences between the oneand two-injection treatment groups was determined by using the Mann-Whitney U-test.
